)
Visual
test
Suzhou Ribo Life Science
Suzhou Ribo Life Science (6938) investor relations material
Suzhou Ribo Life Science H2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2025 earnings summary25 Mar, 2026
Executive summary
Revenue rose 4.1% year-over-year to RMB148.5 million, driven by collaboration/licensing and nucleoside monomer sales.
Gross profit increased 3.3% to RMB135.0 million, with gross margin slightly down to 90.9% due to product mix.
Net loss widened to RMB288.5 million, mainly due to higher listing and administrative expenses.
R&D expenses remained stable at RMB280.5 million, reflecting ongoing investment in pipeline development.
Major pipeline progress includes multiple siRNA drug candidates advancing through global clinical trials, with strategic partnerships expanding reach.
Financial highlights
Revenue: RMB148.5 million (+4.1% YoY); Gross profit: RMB135.0 million (+3.3% YoY).
Gross margin: 90.9% (down 0.8pp YoY); Administrative expenses: RMB118.4 million (+28.0% YoY).
Net loss: RMB288.5 million (vs. RMB281.5 million prior year); Loss per share: RMB2.11.
Cash and cash equivalents: RMB406.7 million (up from RMB167.9 million); Borrowings: RMB522.4 million.
Gearing ratio improved to 120.6% (from 134.6%); Net current liabilities reduced to RMB84.4 million.
Outlook and guidance
Plans to accelerate global development and commercialization of leading drug candidates, including Vortosiran and RBD7022.
Targeting 2–4 new clinical-stage programs annually, with focus on expanding extra-hepatic delivery platforms.
Strategic collaborations and dual-pronged commercialization strategy to maximize product value.
Madrigal MASH collaboration financial terms
Vortosiran safety advantages over DOACs
Status of RiboOncoSTAR and RiboPepSTAR platforms
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Suzhou Ribo Life Science earnings date
H1 20262 Sep, 2026
Suzhou Ribo Life Science
Next Suzhou Ribo Life Science earnings date
H1 20262 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage